These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28642301)

  • 1. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
    Golay J; Ubiali G; Introna M
    Haematologica; 2017 Oct; 102(10):e400-e403. PubMed ID: 28642301
    [No Abstract]   [Full Text] [Related]  

  • 2. Acalabrutinib: First Global Approval.
    Markham A; Dhillon S
    Drugs; 2018 Jan; 78(1):139-145. PubMed ID: 29209955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
    Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
    Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
    J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
    Wu J; Zhang M; Liu D
    J Hematol Oncol; 2016 Mar; 9():21. PubMed ID: 26957112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.
    Bossory Goike L; Dean S
    Vasc Med; 2020 Jun; 25(3):281-282. PubMed ID: 32146868
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
    Niemann CU; Mora-Jensen HI; Dadashian EL; Krantz F; Covey T; Chen SS; Chiorazzi N; Izumi R; Ulrich R; Lannutti BJ; Wiestner A; Herman SEM
    Clin Cancer Res; 2017 Oct; 23(19):5814-5823. PubMed ID: 28645939
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
    Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
    Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on acalabrutinib to treat chronic lymphocytic leukemia.
    Blackmon A; O'Brien S
    Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
    Thibaud S; Tremblay D; Bhalla S; Zimmerman B; Sigel K; Gabrilove J
    Br J Haematol; 2020 Jul; 190(2):e73-e76. PubMed ID: 32433778
    [No Abstract]   [Full Text] [Related]  

  • 14. Acalabrutinib for relapsed chronic lymphocytic leukaemia.
    Burki TK
    Lancet Oncol; 2016 Feb; 17(2):e48. PubMed ID: 26710712
    [No Abstract]   [Full Text] [Related]  

  • 15. Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.
    Edlund H; Buil-Bruna N; Vishwanathan K; Wei H; Raman R; de Kock M; He Z; Liu H; Baek M; Ware J; Patel P; Tomkinson H; Sharma S
    Br J Clin Pharmacol; 2022 May; 88(5):2284-2296. PubMed ID: 34532877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.
    Pinney JJ; Blick-Nitko SK; Baran AM; Peterson DR; Whitehead HE; Izumi R; Munugalavadla V; Van DerMeid KR; Barr PM; Zent CS; Elliott MR; Chu CC
    Haematologica; 2022 Jun; 107(6):1460-1465. PubMed ID: 35172559
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Jain P; Kanagal-Shamanna R; San Lucas FA; Nastoupil L; Romaguera J; Fayad L; Oki Y; Westin JR; Medeiros LJ; Wang M; Fowler N
    Br J Haematol; 2018 Sep; 182(5):718-723. PubMed ID: 28771675
    [No Abstract]   [Full Text] [Related]  

  • 18. Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
    Nierman P
    Clin J Oncol Nurs; 2021 Dec; 25(6):687-696. PubMed ID: 34800101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
    Davids MS; Telford C; Abhyankar S; Waweru C; Ringshausen I
    Leuk Lymphoma; 2021 Oct; 62(10):2342-2351. PubMed ID: 33955326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
    Harrington BK; Gardner HL; Izumi R; Hamdy A; Rothbaum W; Coombes KR; Covey T; Kaptein A; Gulrajani M; Van Lith B; Krejsa C; Coss CC; Russell DS; Zhang X; Urie BK; London CA; Byrd JC; Johnson AJ; Kisseberth WC
    PLoS One; 2016; 11(7):e0159607. PubMed ID: 27434128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.